Investing in and advancing your research

Cincinnati Children’s is committed to investing and supporting basic, translational and clinical research. The Innovation Ventures Team is particularly focused on advancing commercially viable research. We have a number of funding programs in place to move your research forward.  Read more below:

Launched in 2012 and facilitated by the Innovation Ventures, the Innovation Fund was created to accelerate marketable projects-helping discoveries reach their full potential. As an internal funding mechanism, the Fund provides up to $100,000 in total direct funding, for one year, to an innovator, or innovation team at Cincinnati Children's. Projects needing proof-of-concept/early stage bridge funding, with a goal of attracting outside investment, are the perfect fit for this internal funding mechanism.

Grant funds are to be used to enable product development and commercialization. Examples include the development of prototypes; human clinical data; pre-clinical data; drug delivery platform/systems; large animal studies; algorithmic diagnostics, as opposed to single biomarker associations; or other advanced pre-commercial research. Applications must fit into one of the following categories: Biologics, cell & tissue therapies; Diagnostics & medical devices; Digital health & care delivery; or Small molecule therapies.

The 2018 Request for Proposals (RFP) was released in early January, with Letters of Intent (LOI and instructions) due in February and invited applications due April 3. Please contact Ginny Van Horne for additional information.

Adare Pharmaceuticals is an expert in providing enhanced medicines that create new possibilities for improved patient health. In 2015, Cincinnati Children's and Adare partnered to establish the Adare Drug Optimization and Repurposing Innovation Fund. The Adare Innovation Fund is a focused opportunity and additional funding stream of the broader Cincinnati Children's Innovation Fund program. 

Applicants with Innovation Fund proposals that repurpose a currently marketed product or known drug for a new indication are eligible. Adare is interested in proposals that either optimize or repurpose a known drug for a new indication. Specifically, Adare is interested in studying known therapeutics that could benefit from improved efficacy, improved adverse event/tolerability profiles, improved pharmacokinetic/pharmacodynamic relationships or be developed for an entirely new purpose. Therapeutics must be available for optimizing or repurposing with no more than 5 years of patent exclusivity remaining. Following completion of the funded research program, Adare will have an exclusive option to enter into a licensing agreement for these projects/intellectual property. Adare offers up to $200,000 in funding over two, one-year installments. 

Note: Year 2 funding is contingent upon the successful completion of milestones.

Please contact Ginny Van Horne for additional information.

Cincinnati Children's (CCHMC) has two pediatric medical device funds and collaborations. Each effort is designed to develop commercially viable, pediatric specific, medical devices. The structure of each program is different, but all have the same intention of starting pediatric medical device companies in SW Ohio. Below is a brief description of each fund:

  • The Ben-Gurion Cincinnati Children’s Collaborative (BG3C) is a collaborative between Ben-Gurion University of the Negev in Israel and Cincinnati Children's. The collaboration addresses the lack of medical devices designed specifically for children, identifying projects that need to be funded beyond design and development and combining the medical expertise of physicians at Cincinnati Children's with the extensive technical and engineering capabilities of faculty at BGU. The goal is to improve health outcomes by ensuring device design is customized to meet the unique physiological differences and medical needs of children. The collaboration identifies and funds up to three projects each year that meet a medical need and have a strong pathway to commercialization. Each project receives up to $100,000 in funds.
  • University of Dayton – Cincinnati Children's has partnered with the University of Dayton School of Engineering Innovation Center to develop a pathway for creating pediatric medical devices that meet an unmet medical need. Each project is assigned a team of students and a lead faculty member to move the project through a development pipeline. Since 2013, we have worked on one to two projects per year.

Please contact The Innovation Ventures Team for additional information.

The NIH Centers for Accelerated Innovations (NCAI) program, funded by the National Institute of Health's (NIH) National Heart, Lung, and Blood Institute (NHLBI), targets technologies to improve the prevention, diagnosis, treatment, and management of heart, lung, blood, and sleep disorders, involving projects that span the technology range of diagnostics, diagnostic systems, devices, therapeutics and tools. Cincinnati Children's, Case Western University, the University of Cincinnati, Northwestern University, University of Michigan, and The Ohio State University are partners in the NCAI program, which is led by Cleveland Clinic.

Funding Cycle: Request for Applications (RFA) are generally released in January and June. Funds are allocated to specific, measurable project development activities that are key to establishing commercial opportunity. Project scope encompasses work that leads to critical project milestones that can be accomplished within one year, and which serve to enable follow-on funding from later stage investment sources such as other federal programs (e.g., SMARTT, SBIR/STTR), other state programs (e.g. Ohio Third Frontier, Global Cardiovascular Innovation Center), venture capital or industry.

Available Funding: A total of up to $150,000 in direct cost budget may be made available per project, for one year, comprised of up to $75,000 in federal funds from the NCAI program plus an equal amount in required non-federal matching funds (ratio of $1 to $1). Funding awards will be in the form of a grant. Matching funds will come from the Cincinnati Children's Innovation Ventures office.

Requirements: Applications submitted should be for projects directed towards achievement of critical development milestones with the objective of advancing the technology towards commercialization. Projects must be directed towards development of diagnostics, devices, therapeutics or tools in clinical application areas directly related to cardiovascular, lung, blood or sleep disorders.

Use of NCAI funds should be directly allocated to specific, measurable project activities that are key to establishing commercial opportunity, and on a timeline covering a period of approximately one year from grant of the award.

Note: for therapeutics development projects, it is strongly recommended that the PI have a lead compound identified with disease target validated by appropriate screening assays along with initial indication of efficacy in-vivo in order for the project to be considered at an appropriate stage for program funding.

Questions? Please contact Ginny Van Horne with questions. Please also visit the NCAI site for additional information.

GlaxoSmithKline (GSK) R&D is collaborating with Cincinnati Children’s to identify and advance innovative therapies. GSK is looking for researchers who:

  • Want to be involved in turning their innovative research into medicines
  • Will contribute their effort and resources to making projects work
  • Are recognized experts in their field
  • Bring unique capabilities to the collaboration

GSK's Discovery Partnerships with Academia (DPAc) is a unique approach to early drug discovery that is designed to provide industrial drug discovery resources and expertise to academic researchers.

Please contact Ginny Van Horne at 513-803-1175 for additional information.

Cincinnati Children's participates in Eli Lilly's Open Innovation Drug Discovery (OIDD) Program. Principal Investigators can have access to the same tools and expertise available to Lilly's scientists to design, test, and make new molecules. Examples include cutting-edge computational tools, in vitro biological assays, quality-designed privileged molecular libraries, and synthetic technologies.

Please note that all submitted compounds should be at least 90% pure based on contemporary analytical characterization. Compound mixtures are not acceptable.

Principal Investigators retain complete control of their intellectual property.

If you are interested in accessing the OIDD library, we will help you create an individual account. Please contact Ginny Van Horne at 513-803-1175 for additional information.